(1S,2S)-2-((4-((3,5-Dichloro-1H-pyrazol-1-yl)methyl)-6-methyl-2-oxopyridin-1(2H)-yl)methyl)cyclopropane-1-carbonitrile

ID: ALA5284167

Chembl Id: CHEMBL5284167

Max Phase: Preclinical

Molecular Formula: C15H14Cl2N4O

Molecular Weight: 337.21

Associated Items:

Names and Identifiers

Canonical SMILES:  Cc1cc(Cn2nc(Cl)cc2Cl)cc(=O)n1C[C@H]1C[C@@H]1C#N

Standard InChI:  InChI=1S/C15H14Cl2N4O/c1-9-2-10(7-21-14(17)5-13(16)19-21)3-15(22)20(9)8-12-4-11(12)6-18/h2-3,5,11-12H,4,7-8H2,1H3/t11-,12-/m1/s1

Standard InChI Key:  YETRMVOJZJWDLM-VXGBXAGGSA-N

Alternative Forms

  1. Parent:

    ALA5284167

    ---

Associated Targets(Human)

GRIN2A Tclin Glutamate [NMDA] receptor subunit epsilon 1 (112 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
GRIA2 Tclin Glutamate receptor ionotropic, AMPA 2 (847 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 337.21Molecular Weight (Monoisotopic): 336.0545AlogP: 2.87#Rotatable Bonds: 4
Polar Surface Area: 63.61Molecular Species: NEUTRALHBA: 5HBD:
#RO5 Violations: HBA (Lipinski): 5HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 0.54CX LogP: 1.53CX LogD: 1.53
Aromatic Rings: 2Heavy Atoms: 22QED Weighted: 0.86Np Likeness Score: -1.33

References

1. Yukawa T, Yamashita T, Imaeda T, Kakei H, Hashizume S, Nakamura M, Daini M, Okabe A, Nakashima K, Harada A, Narita N, Bettini E, Ugolini A, Corsi M, Hasui T..  (2023)  Design and synthesis of 6-methylpyridin-2-one derivatives as novel and potent GluN2A positive allosteric modulators for the treatment of cognitive impairment.,  79  [PMID:36640594] [10.1016/j.bmc.2022.117150]

Source